Cosmo Pharmaceuticals (CMOPF) News Today C$95.00 0.00 (0.00%) (As of 11/14/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGMOctober 19, 2024 | stockhouse.comCosmo Pharmaceuticals Appoints New Chief Financial OfficerOctober 11, 2024 | stockhouse.comCosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...October 9, 2024 | finance.yahoo.comCosmo Chemical Co LtdSeptember 20, 2024 | reuters.comCMOPF Cosmo Pharmaceuticals N.V.September 7, 2024 | seekingalpha.comFree food, endless TV and… the flu? This is what it’s like to take part in a paid medical trialAugust 11, 2024 | msn.comCosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA ClearanceJuly 31, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. (CMOPF)July 26, 2024 | ca.finance.yahoo.comCosmo Pharmaceuticals NV's Dividend AnalysisMay 27, 2024 | finance.yahoo.comCosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General MeetingMay 24, 2024 | finance.yahoo.comCosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023April 29, 2024 | finance.yahoo.comDespite concern about older adults living alone, these seniors prefer the solo life: 'I love not having to answer to anyone else'April 29, 2024 | msn.comCosmo Announces Leadership ChangesApril 25, 2024 | finance.yahoo.comQ4 2023 Paysign Inc Earnings CallMarch 28, 2024 | finance.yahoo.comBullish: Analysts Just Made A Massive Upgrade To Their Cosmo Pharmaceuticals N.V. (VTX:COPN) ForecastsMarch 28, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarch 23, 2024 | finance.yahoo.comCosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per ShareMarch 20, 2024 | finance.yahoo.comCosmo Pharmaceuticals Announces Approval of Winlevi(R) in AustraliaMarch 19, 2024 | finance.yahoo.comSay Hi to the Cosmo Trend Report: A Comprehensive Look at All the Things You’re Gonna Want to Wear This SpringMarch 15, 2024 | msn.comCosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 18% loss from investing in the stock three years agoMarch 13, 2024 | finance.yahoo.comGibson to open huge guitar store in West End on SaturdayFebruary 23, 2024 | msn.comPupils unwell after school lab chemical spillFebruary 22, 2024 | au.news.yahoo.comCosmo Pharmaceuticals N.V.February 20, 2024 | wsj.comCosmoprof North America Miami Celebrates Its Inaugural Edition with Overwhelming Success with over 19,000 VisitsFebruary 1, 2024 | markets.businessinsider.comInvitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024January 25, 2024 | finance.yahoo.comBrokers Are Upgrading Their Views On Cosmo Pharmaceuticals N.V. (VTX:COPN) With These New ForecastsJanuary 5, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. (VTX:COPN) Stocks Shoot Up 37% But Its P/S Still Looks ReasonableDecember 18, 2023 | finance.yahoo.comMarket Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues Pushing Shares 37% HigherDecember 18, 2023 | finance.yahoo.comCosmo Pharmaceuticals NV CMOPFNovember 23, 2023 | morningstar.comCosmo Pharmaceuticals N.V.'s (VTX:COPN) top owners are private companies with 47% stake, while 35% is held by individual investorsNovember 23, 2023 | finance.yahoo.comCosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 68% loss from investing in the stock five years agoOctober 5, 2023 | finance.yahoo.comCosmo, Glenmark Sign Distribution And License Agreements For Winlevi In Europe, South AfricaSeptember 27, 2023 | msn.comCosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South AfricaSeptember 27, 2023 | benzinga.comCOSMO Pharmaceuticals SA (COPN)September 16, 2023 | investing.comCosmo Pharmaceuticals N.V.'s (VTX:COPN) P/E Still Appears To Be ReasonableSeptember 14, 2023 | finance.yahoo.comCosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 58% loss from investing in the stock five years agoSeptember 14, 2023 | finance.yahoo.comCosmo Pharmaceuticals N.V.'s (VTX:COPN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?September 14, 2023 | finance.yahoo.comCosmo Pharmaceuticals N.V. (VTX:COPN) Is About To Go Ex-Dividend, And It Pays A 2.0% YieldSeptember 14, 2023 | finance.yahoo.comWhile individual investors own 36% of Cosmo Pharmaceuticals N.V. (VTX:COPN), private companies are its largest shareholders with 47% ownershipSeptember 14, 2023 | finance.yahoo.comCosmo Pharmaceuticals First Half 2023 Earnings: EPS Beats Expectations, Revenues LagSeptember 14, 2023 | finance.yahoo.com Get Cosmo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMOPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump Wins… But Elon Says Get Ready to Brace (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov CMOPF Media Mentions By Week CMOPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMOPF News Sentiment▼0.000.54▲Average Medical News Sentiment CMOPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMOPF Articles This Week▼00▲CMOPF Articles Average Week Get Cosmo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMOPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 1933 Industries News Today 4Front Ventures News Today AB Science News Today Aclarion News Today Acreage News Today Acreage News Today ADM Tronics Unlimited News Today Advanced BioMedical Technologies News Today Algernon Pharmaceuticals News Today Alibaba Health Information Technology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTC:CMOPF) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cosmo Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Share Cosmo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
